

Pimurutamab

Chemical Properties

CAS No. : 2251771-76-1

Formula:

Molecular Weight:

Storage: Store at low temperature
Store at -20°C

Actual storage temperature shall be subject to the COA.

Biological Description

Description	Pimurutamab is a humanized monoclonal antibody modified by glycosylation engineering, which specifically targets epidermal growth factor receptor (EGFR/HER1). By binding to the extracellular domain of EGFR, Pimurutamab blocks its binding to ligands such as EGF and TGF- α , and inhibits receptor dimerization and downstream signal transduction. In addition, the optimized glycosylation modification significantly enhanced its antibody-dependent cell-mediated cytotoxicity (ADCC), making it show good potential in the treatment of solid tumors with high EGFR expression.
Targets(IC50)	EGFR
In vitro	In macrophage-mediated phagocytosis assays using human cancer cell lines, Pimurutamab (ATG-031) (nanomolar concentrations) blocked the CD24-Siglec-10 interaction and significantly enhanced the engulfment of tumor cells [1].
In vivo	In human tumor xenograft models, systemic administration of Pimurutamab (ATG-031) significantly suppressed tumor growth and demonstrated synergistic effects when combined with PD-L1 inhibitors [1].

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481